Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21


Frequency and cause of transient QT prolongation after surgery.

Joyce DD, Bos JM, Haugaa KH, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ.

Am J Cardiol. 2015 Nov 15;116(10):1605-9. doi: 10.1016/j.amjcard.2015.08.027. Epub 2015 Sep 3.


Phenotype of Children with QT Prolongation Identified Using an Institution-Wide QT Alert System.

Anderson HN, Bos JM, Haugaa KH, Morlan BW, Tarrell RF, Caraballo PJ, Ackerman MJ.

Pediatr Cardiol. 2015 Oct;36(7):1350-6. doi: 10.1007/s00246-015-1164-y. Epub 2015 Apr 7.


Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes.

Sorita A, Bos JM, Morlan BW, Tarrell RF, Ackerman MJ, Caraballo PJ.

J Am Med Inform Assoc. 2015 Apr;22(e1):e21-7. doi: 10.1136/amiajnl-2014-002896. Epub 2014 Oct 16.


Impact of left ventricular hypertrophy on QT prolongation and associated mortality.

Haugaa KH, Bos JM, Borkenhagen EJ, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ.

Heart Rhythm. 2014 Nov;11(11):1957-65. doi: 10.1016/j.hrthm.2014.06.025. Epub 2014 Jun 20.


Widely used track and trigger scores: are they ready for automation in practice?

Romero-Brufau S, Huddleston JM, Naessens JM, Johnson MG, Hickman J, Morlan BW, Jensen JB, Caples SM, Elmer JL, Schmidt JA, Morgenthaler TI, Santrach PJ.

Resuscitation. 2014 Apr;85(4):549-52. doi: 10.1016/j.resuscitation.2013.12.017. Epub 2014 Jan 7.


Evaluating implementation of a rapid response team: considering alternative outcome measures.

Moriarty JP, Schiebel NE, Johnson MG, Jensen JB, Caples SM, Morlan BW, Huddleston JM, Huebner M, Naessens JM.

Int J Qual Health Care. 2014 Feb;26(1):49-57. doi: 10.1093/intqhc/mzt091. Epub 2014 Jan 8.


Institution-wide QT alert system identifies patients with a high risk of mortality.

Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ.

Mayo Clin Proc. 2013 Apr;88(4):315-25. doi: 10.1016/j.mayocp.2013.01.013.


miRNA expression in colon polyps provides evidence for a multihit model of colon cancer.

Oberg AL, French AJ, Sarver AL, Subramanian S, Morlan BW, Riska SM, Borralho PM, Cunningham JM, Boardman LA, Wang L, Smyrk TC, Asmann Y, Steer CJ, Thibodeau SN.

PLoS One. 2011;6(6):e20465. doi: 10.1371/journal.pone.0020465. Epub 2011 Jun 9.


Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial.

Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP.

Am J Clin Oncol. 2012 Oct;35(5):418-23.


Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.

Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S.

Am J Clin Oncol. 2012 Aug;35(4):329-33. doi: 10.1097/COC.0b013e3182118cdf.


Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance.

Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, Ballman KV, Giannini C, Sarkaria JN.

J Neurooncol. 2010 Nov;100(2):177-86. doi: 10.1007/s11060-010-0186-9. Epub 2010 May 5.


Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states.

Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM, Subramanian S, Wang L, Smyrk TC, Rodrigues CM, Thibodeau SN, Steer CJ.

BMC Cancer. 2009 Nov 18;9:401. doi: 10.1186/1471-2407-9-401.


Evaluation of a new high-dimensional miRNA profiling platform.

Cunningham JM, Oberg AL, Borralho PM, Kren BT, French AJ, Wang L, Bot BM, Morlan BW, Silverstein KA, Staggs R, Zeng Y, Lamblin AF, Hilker CA, Fan JB, Steer CJ, Thibodeau SN.

BMC Med Genomics. 2009 Aug 27;2:57. doi: 10.1186/1755-8794-2-57.


Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19.

Drucker KL, Kitange GJ, Kollmeyer TM, Law ME, Passe S, Rynearson AL, Blair H, Soderberg CL, Morlan BW, Ballman KV, Giannini C, Jenkins RB.

Genes Chromosomes Cancer. 2009 Oct;48(10):854-64. doi: 10.1002/gcc.20688.


A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.

Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, Asmann YW, Klee GG, Ballman KV, Jenkins RB.

PLoS One. 2008;3(5):e2318. doi: 10.1371/journal.pone.0002318. Epub 2008 May 28.


P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, Toft DO, Erlichman C.

Cancer Res. 2008 Sep 15;68(18):7419-27. doi: 10.1158/0008-5472.CAN-07-5175.


Colorectal cancer risks in relatives of young-onset cases: is risk the same across all first-degree relatives?

Boardman LA, Morlan BW, Rabe KG, Petersen GM, Lindor NM, Nigon SK, Goldberg J, Gallinger S.

Clin Gastroenterol Hepatol. 2007 Oct;5(10):1195-8. Epub 2007 Aug 16.


Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

McWilliams RR, Goetz MP, Morlan BW, Salim M, Rowland KM, Krook JE, Ames MM, Erlichman C.

Clin Colorectal Cancer. 2007 May;6(7):516-21.


Higher frequency of diploidy in young-onset microsatellite-stable colorectal cancer.

Boardman LA, Johnson RA, Petersen GM, Oberg AL, Kabat BF, Slusser JP, Wang L, Morlan BW, French AJ, Smyrk TC, Lindor NM, Thibodeau SN.

Clin Cancer Res. 2007 Apr 15;13(8):2323-8.


PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.

Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CY.

Clin Cancer Res. 2006 Feb 15;12(4):1128-36.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk